-
Zoetis Capitalizing On Lack Of Competition In Generic Animal Drug Competition
Friday, September 9, 2016 - 10:29am | 414Read More...Argus’ Jacob Kilstein believes Zoetis Inc (NYSE: ZTS) has been benefiting from a “lack of generic competition in the animal drug space.” Kilstein maintains a Buy rating on the company, while raising the price target from $54 to $58. Benefiting From Animal Drug Space The analyst...
-
Citi Downgrades Zoetis, Cites Valuation
Friday, June 10, 2016 - 9:39am | 244Read More...Zoetis Inc (NYSE: ZTS) has been meaningfully outperforming specialty pharma peers year-to-date. Citi’s Liav Abraham downgraded the company from Buy to Neutral, while raising the price target from $46 to $50. Upside Unlikely While maintaining a constructive stance on Zoetis’ fundamentals...
-
No Growth For Zoetis; Analysts Expect Flat YOY Earnings
Monday, May 4, 2015 - 1:58pm | 344Read More...Shares of Zoetis Inc (NYSE: ZTS) were up 1.5 percent on Monday, in anticipation of Tuesday’s earnings call. The company is scheduled to report its first quarter financial results on Tuesday before the market opens. According to Estimize, the Street expects to see no earnings growth. In...
